Firms

FemHealth Ventures

FemHealth Ventures is a Short Hills, New Jersey venture capital firm investing in women’s health across drugs, medical devices, diagnostics and digital or AI-enabled technologies. Its framework covers conditions occurring only in women, mostly in women or differently in women. Relevant investments include Reunion Neuroscience’s investigational postpartum depression treatment, Cercle’s AI-based health data platform and Mendaera’s medical robotics. The firm pairs investment professionals with an advisory board spanning biotechnology, healthcare investing, medicine and business. It reported a USD32 million debut fund closing in 2023 and announced a USD65 million Fund II closing in December 2025, reporting USD100 million of aggregate assets under management across two funds. Aggregate AUM is separate from individual disclosed closing amounts.

Founded: —
Type: Venture capital

Funds2

FemHealth Ventures Fund II2025-12-172025-12-17$65M
Second women’s health venture fund, announced closed oversubscribed at USD65 million in December 2025. Continues investing in drugs, devices, diagnostics and digital or AI-enabled technologies. USD100 million is the manager’s reported aggregate AUM across two funds, not this vehicle’s size.
FemHealth Ventures Fund I—$32M
Debut women’s health venture fund launched in 2021. The manager’s September 2023 news reports a USD32 million closing; this is the disclosed historical closing amount. Later aggregate AUM reporting does not establish an individually disclosed subsequent fund size, and no exact final-closing day is asserted.